High expectation on ‘Lynparza,’ BRCA-mutated ovarian cancer targeted treatment

Published: 2016-01-28 13:01:40

Updated: 2016-01-28 13:01:51

‘Lynparza,’ a targeted therapy for ovarian cancer known for its low survival rate and high recurrence rate, was launched in Korea.

On the 26^th, AstraZeneca Korea(hereinafter referring to AZ) announced the launch of ‘Lynparza(generic name: olaparib),’ the first ovarian cancer targeted therapy using biomarkers in diagnosis.

Lynparza is the domestically first ovarian cancer targeted treatment wh...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.